C. Difficile

>

Latest News

Investigational Oral Biologic Achieves 100% C difficile Clinical Cure in Preliminary Cohort
Investigational Oral Biologic Achieves 100% C difficile Clinical Cure in Preliminary Cohort

April 3rd 2025

Lumen Bioscience’s, LMN-201, was considered safe and well-tolerated and there were no severe dose-related or serious adverse events reported.

New Meta-Analysis Highlights Most Effective Treatments for Clostridioides difficile Infection
New Meta-Analysis Highlights Most Effective Treatments for Clostridioides difficile Infection

February 6th 2025

Investigational Live Biotherapeutic Product Significantly Reduces Risk of Recurrent Clostridioides difficile
Investigational Live Biotherapeutic Product Significantly Reduces Risk of Recurrent Clostridioides difficile

January 24th 2025

LPOXY Therapeutics Acquires Assets to Advance C difficile Protection for Antibiotic Patients
LPOXY Therapeutics Acquires Assets to Advance C difficile Protection for Antibiotic Patients

January 8th 2025

Contagion's 2024 Top Stories: C difficile
Contagion's 2024 Top Stories: C difficile

December 28th 2024

Video Series
Video Interviews
Podcasts

More News

© 2025 MJH Life Sciences

All rights reserved.